Tests virus-fighting T cells for viral infections in children and young adults
Tests immune cells against viral infections in immunodeficient children and young adults.
Key facts
- Who runs it
- Monica Bhatia
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 18 people, planned
- Started
- 20 Apr 2025
- Expected to end
- Dec 2030
- Type of study
- Interventional, 3 groups
- Treatments tested
- Rapidly generated virus specific T (R-MVST) cells
- Record updated
- 30 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults who had a stem cell or organ transplant and have a virus (EBV, CMV, ADV or BK) that does not respond well to standard treatment.
- Age
- 3 months to under 26 years
- Sex
- All sexes can join.
- Disease stage
- Viral reactivation or infection (EBV, CMV, ADV or BK virus) causing organ or body-wide disease, with a poor response to standard treatment. Repeated or multiple viral infections can also count.
- Earlier treatment
- Must have had a stem cell (HCT) or solid organ (SOT) transplant and standard treatment that did not work well enough. Recent T-cell-lowering drugs, methotrexate, photopheresis, checkpoint inhibitors or donor lymphocyte infusion are not allowed within set time limits.
- Biomarker or test result
- Virus found by PCR test for repeated or multiple infections.
Main reasons for not taking part
- Other uncontrolled infections
- Steroids at 0.5mg/kg prednisone or more
- GVHD grade 2 or higher
- Active, uncontrolled relapse of cancer
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Children and young adults (3 months to <26 years) of all ethnic groups will be eligible for the treatment
- Patients with history of HCT or SOT who demonstrate evidence of viral reactivation and/or infection manifesting as end-organ or systemic disease due to one or more of the following viruses: EBV, CMV, ADV or BK virus and suboptimal response to the standard of care therapy
- Recurrent or Multiple Viral Infection. RVI defined as occurrence of more than one episode of reactivation that required intervention or symptomatic disease in recipient of allogeneic HCT that required standard of care treatment. MVI defined as more than one virus reactivating (defined by PCR positivity) or causing symptomatic systemic or end-organ disease. At least one of those viral reactivations required standard of care intervention. No standard of care therapy is defined for ADV and BK. Patients with multiple infections/reactivations will be eligible as long as at least one of those viral infections meet the criterium of "refractory"
Who cannot take part
- Patients with other uncontrolled infections, except for CMV, EBV, ADV or BK. For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to the day of infusion. For fungal infections, patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to R-MVST infusion. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection
- Patients who receive corticosteroids at ≥ 0.5mg/kg prednisone or equivalent
- Patients who received anti-thymocyte globulin (ATG, Alemtuzumab (Campath), or other T-Cell immunosuppressive monoclonal antibodies in the last 28 days
- Patients who received methotrexate, or other antimetabolite-type immunosuppressants that are toxic to proliferating T cells in the last 7 days
- Patients who received extracorporeal photopheresis within the last 28 days
- Patients who received checkpoint inhibitor agents (e.g., nivolumab, pembrolizumab, ipilimumab) within 3 drug half-lives of the most recent dose to the infusion of R-MVST
- Patients who have received investigational (IND) product within 14 days of infusion of the the R-MVST cells
- Active and uncontrolled relapse of malignancy
- Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Received donor lymphocyte infusion in last 28 days
- Evidence of GVHD ≥ grade 2
- Evidence of biopsy-proven acute rejection in SOT recipients
- Patients who are pregnant, or breastfeeding
- Female of childbearing potential, or male with a female partner of childbearing potential, unwilling to use a highly effective method of contraception
- Unable or unwilling to receive infusions at Morgan Stanley Children's Hospital
Where in United States
- Columbia University Medical Center New York PresbyterianNew York, United StatesContact: Haneen AljayyousiTaking people
About the trial
What the trial wants to find out
The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available. The investigator will closely monitor the recipients for potential toxicities including graft-versus-host disease (GVHD) post-infusion.
Read full original descriptionShow less
Secondary objectives are to determine the effect of R-MVST infusion on viral load, possible recovery of antiviral immunity post-infusion and for evidence of clinical responses and overall survival. Recipients will be monitored for secondary graft failure at day 28 post R-MVST infusion.
The 3 groups in the trial
- Group A: Allogenic Stem Cell Transplant RecipientsTreatment being tested
Patients who have infection due to cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus or BK virus, and are recipients of hematopoietic stem cell transplant.
Treatment: Rapidly generated virus specific T (R-MVST) cells
- Group B: Solid Organ Transplant RecipientsTreatment being tested
Patients who have infection due to cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus or BK virus, and are recipients of solid organ transplant.
Treatment: Rapidly generated virus specific T (R-MVST) cells
- Group C: Other Immunocompromised PatientsTreatment being tested
Patients who have infection due to cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus or BK virus, and are immunocompromised for reasons other than hematopoietic stem cell transplant or solid organ transplant.
Treatment: Rapidly generated virus specific T (R-MVST) cells
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Single Center Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection With ex Vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells for Immunodeficient Children and Young Adults
- Plain-language title
- Tests virus-fighting T cells for viral infections in children and young adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 July 2026